Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Yungjin Pharm Co. Ltd. maintains a concentrated patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action, which constitutes its entire active prosecution workload. This matter is assigned to 1 distinct examiner, AL-AWADI, DANAH J. As the busiest examiner for the portfolio, AL-AWADI, DANAH J is handling 1 pending case. This singular focus suggests that the company's immediate goals in the Biotechnology & Pharmaceuticals sector are being managed through a unified official channel.
The portfolio is limited to 1 distinct art unit, which suggests a very specific technical focus. This narrow distribution means that the company's prosecution strategy is not spread across different examination groups. For a practitioner, the existence of 1 pending office action provides an opportunity for a dedicated and precise response to the examiner's requirements. Since there is only 1 distinct examiner involved, the company can focus on addressing the specific preferences of AL-AWADI, DANAH J. The concentration in 1 distinct art unit ensures that the technical arguments are evaluated by a single specialized group, providing a consistent environment for the company's patent development.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AL-AWADI, DANAH J | 1 | 54.3% | +13.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919855 | ENTERIC-COATED PREPARATION COMPRISING PIRFENIDONE HAVING IMPROVED SAFETY AND STABILITY, AND METHOD FOR PREPARING SAME | AL-AWADI, DANAH J | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17919855 | ENTERIC-COATED PREPARATION COMPRISING PIRFENIDONE HAVING IMPROVED SAFETY AND STABILITY, AND METHOD FOR PREPARING SAME | AL-AWADI, DANAH J | 1615 | §103 | Final Rejection | — | Pending | Oct 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYungjin Pharm Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Danah J Al-Awadi has the most, with 1 of Yungjin Pharm Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.